JOURNAL CONTENT
CONTACT

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

THE RULES OF SUBMITTING AN ARTICLE

READ

Scimago Journal & Country Rank

SCImago Journal & Country Rank

LECTION

    1. Center for Strategic Planning Russian Ministry of Health
    2. SM Kirov Military Medical Academy
    3. AI Evdokimov Moscow State Medical-Stomatological University, Ministry of Health
    4. Central State Medical Academy
    5. Kraft LLC

    Keywords: microbe/host cross talk, probiotic microorganisms, bioactive molecules, microbial structural components, metabolites, signaling molecules, simple and complex hybrid metabiotics

    Abstract:The human symbiotic microbiota produces various bio-active molecules having chemical and functional similarity to dietary nutrients and /or endogenous compounds. Various factors and agents cause the imbalance of host/microbial dialogue. Currently for conservation and restoration of human microbial community various probiotics and prebiotics are used. Unfortunately, probiotic effects are often short term or absent or uncertain; traditional probiotics may also have non-desirable side effects in the application. For these reasons, the search for microbial molecule modifiers of host/microbe axis is emerging, especially with regard to personal medicine. These compounds have been named metabiotics (M). M are structural components of known probiotic microorganisms and/or their metabolites and/or signaling molecules that can restoring shortages and disruption of the balance of mitochondrial, microbial or cellular LMW substances with increased health effectiveness. They have some advantages (certain chemical structure, well dosed, safety, long shelf-life) in optimizing host gene expression, epigenetic, energetic, metabolic, immune, informational, regulatory, transport, neuro-hormonal and/or behavioral responses associated with the symbiotic microbiota. M can act as independent means or as enriching additives in functional foods. Simple microbial molecules can also be used in constructing hybrid M containing multiple metabolites and structural components separately or in combination with herbal compounds. Special attention should be paid to the design of M with specific targets in the host. Further investigations will clarify what natural microbial or artificial (semi-synthetic, synthetic, hybolite) pan- or selective M may affect host functions, biochemical and signal processes.

      1. Ugolev A. M. Teoriya adekvatnogo pitaniya i Trofologiya- L. Nauka, 1991. - 372 s.
      2. Lederberg J. Infectious history. Science 2000; 288: 287-289.
      3. Tkachenko E. I. Paradigma disbioza v sovremennoy gastroenterologii. Rol’ mikrobioty v lechenii i profilaktike zabolevaniy v XXI veke. Eksperimental’naya i klinicheskaya gastroenterologiya. 2014; 105(5):4-7.
      4. Prescott S.L. History of medicine: Origin of the term microbiome and why it matterns. Human Microbiome Journal 2017; 4: 24-25.
      5. Shenderov B. A., Sinitsa A. V., Zakharchenko M. M. Metabiotiki: vchera, segodnya, zavtra. Sankt-Peterburg. OOO “Kraft”, 2017. - 80 s.
      6. Shenderov B. A. Modern condition and prospective host microecology investigations. Microb Ecol Health Dis 2007; 19: 145-149.
      7. Shenderov B. A. Mikrobnaya ekologiya cheloveka i yeye rol’ v podderzhanii zdorov’ya. METAFORMOZY. 2014; № 5:72-80.
      8. Shenderov B. A. Metabiotiki - novaya tekhnologiya profilaktiki zabolevaniy, svyazannykh s mikroekologicheskim disbalansom cheloveka. Vestnik vosstanovitel’noy meditsiny 2017; № 4: 40-49.
      9. Li J, Jia H, Cai X, Zhong H, Feng Q, Sunagawa S. et al. An Integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol 2014; 32: 834-41.
      10. Gaci N., m Borrel G., Tottey W., O’Toole P/W, Brugere J-F. Archaea and the human gut: New beginning of an old story. World Journal of Gastroenterology 2014; 20(43): 16062-16078.
      11. Ardatskaya M. D., Bel’mer S. V., Dobritsa V. P., Zakharenko S. M., Lazebnik L. B., Minushkin O. N., Oreshko L. S, Sitkin S. I., Tkachenko E. I., Suvorov A. N., Khavkin A. I., Shenderov B. A. Disbioz (disbakterioz) kishechnika: sovremennoye sostoyaniye problemy, kompleksnaya diagnostika i lechebnaya korrektsiya. Eksperimental’naya i klinicheskaya gastroenterologiya 2015; 117 (5):13-50.
      12. Falony G., Joossens M., Viera-Silva S., Wang J., Darzi Y., Faust K., Kurilshikov A., Bonder M. J., Valles-Colomer M., Vandeputte D, Tito RY, Chaffron S., Rymenans L. et al. Population-level analysis of gut microbiome variation. Science 2016; 352 (6285): 560-564; DOI: 10.1126/science.aad3503.
      13. Zhernakova A, Kurilshikov A, Bonder M. J., Tigchelaar E.F, Schirmer M, Vatanen T. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 2016; 352: 565-569.
      14. Proal A. D., Lindseth I.A, Marshall T. G. Microbe-Microbe and Host- Microbe Interactions Drive Microbiome Dysbiosis and Inflammatory Processes. Discovery Medicine 2017; 23(124): 51-60.
      15. Blum H.E. The human microbiome. Advance in Medical Sciences 2017;62:414-20.http://dx.doi.org/10.1016/j.advms.2017.04.005.
      16. Bik E. M., Ugalde J. A., Cousins J., Goddard A. D., Richman J., Apte Z. S. Microbial biotransformations in the human distal gut. British J Pharmacology 2017. DOI:10.1111/bph.14085.
      17. Sonnenburg JL, Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature 2016; 536: 56–64.
      18. Badretdinova L. M., Batregdinova R. R., Shenderov B. A. Sanatorno-kurortnoye lecheniye osteoartroza. Sovremennoye sostoyaniye i perspektivy. Yekaterinborg.: Izdatel’stvo AMB, 2012. - S. 99-117.
      19. Shenderov B. A. Probiotic (symbiotic) bacterial languages. Anaerobe 2011; 17: 490-495.
      20. Shenderov B.A. PROBIOTICS AND FUNCTIONAL FOODS, in Food Engineering, [Eds. UNESCO-EOLSS Joint Committee], in Encyclopedia of Life Support Systems (EOLSS), Developed under the Auspices of the UNESCO, Eolss Publishers, Oxford, UK, [http://www.eols.net]. 2011; 33p.
      21. Shenderov B.A, Midtvedt T. Epigenomic programing: a future way to health? Microbial ecology in Health & Disease 2014, 25: 24145 - http://dx.doi.org/10.3402/mehd.v25.24145.
      22. Stilling, R.M., Dinan, T.G., Cryan, J. F. Microbial genes, brain & behavior - epigenetic regulation of the gut-brain axis. Genes Brain Behav. 2014; 13 (1): 69-86. doi: 10.1111/gbb.12109.
      23. Galand, L. The gut microbiome and the brain. J Med Food. - 2014. - Dec. - Vol. 17 (12): 1261-72. - doi: 10.1089/jmf.2014.7000.
      24. Sampson, T.R., Mazmanitan, S. K. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 2015; 17 (5): 565-576. doi: 0.1016/j.chom.2015.04.011.
      25. Paul B., Barnes S., S. Demark-Wahnefried S, Morrow C, Salvador C, Skibola C, Tollrfboll OT. Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases. Clinical Epigenetics 2015; 7.112. Doi:10.1186/s13148-015-0144-7.
      26. Oleskin A. V., El’-Registan G.I., Shenderov B. A. Mezhmikrobnyye khimicheskiye vzaimodeystviya i dialog mikrobiota-khozyain: rol’ neyromediatorov. Mikrobiologiya 2016; 85(1): 1-24.
      27. Oleskin A.V, Shenderov B.A, Rogovsky V.S. Role of Neurochemicals in the Interaction between the Microbiota and the Immune and the Nervous System of the Host Organism. Probiotics and Antimicrobial Proteins, February 2017. DOI: 10.1007/s12602-017-9262-1.
      28. Shenderov B.A. Metabiotics: novel idea or natural development of probiotic conception. Microb Ecol Health Dis 2013; 24: 20399-http:// dx.doi. org/10.3402/mehd.v24i0.20399.
      29. Sharma M, Shukla G. Metabiotics: One Step ahead of Probiotics; an Insight into Mechanisms Involved in Anticancerous Effect in Colorectal Cancer. Front Microbiol 7:1940. Doi: 10.3389/fmicb.2016.01940.
      30. Beloborodova N.V, Osipov G.A. Small molecules originating from microbes (SMOM) and their role in microbes-host relationship. Microb Ecol Health Dis 2000; 12:12e21.
      31. Nicolson G. L., Mattos de G.F., Settineri R., Costa C., Ellithorpe R., Rosenblatt S., Valle La J., Jimenez A., Ohta S. Clinical effects of hydrogen administration: from animal and human diseases to exercise medicine. Intern J Clin Medicine 2016; 7: 32-76. doi.org/10.4236/ijcm.2016.71005
      32. Lazebnik L. B., Konev Yu. V. Mikrobiota tolstoy kishki i sostavlyayushchiye metabolicheskogo sindroma // Eksperimental’naya i klinicheskaya gastroenterologiya. - 2014. - № 5. - S. 33-39.
      33. Ardatskaya M. D. Probiotiki, prebiotiki i metabiotiki v korrektsii mikroekologicheskikh narusheniy kishechnika. Meditsinskiy Sovet 2015; № 3: 94-9.
      34. Gibson G.R, Hutkins R, Sanders M.E, Prescott S.L, Reimer R.A, Salminen S.J. et al. The nternational scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology & Hepatology. Published online 14 Jun 2017. Doi: 10.1038/nrgast6ro. 2017.75.
      35. Nguen H-T, Truong D-H, Kouhonde S, Ly S, Razafindralambo H, Delvigne F. Biochemical engineering approaches for increasing viability and functionality of probiotic bacteria. Int J Mol Sci 2016 Jun 2; 17(6). pii: E867. Doi: 10.3390/ijms17060867.
      36. Katan A. Why the European Food Safety Authority was right to reject health claims or probiotics. Benefitial Microbes; 2012. 3(2): 85-89.
      37. Hill C, Guarner F, Reid G, Gibson G, Merenstein D, Pot B, Morelli L. et al. The International scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11(8): 506-514. Doi: 10.1038/nrgastro.2014.66.
      38. Vakhitov T. Ya., Sitkin S. I. Kontseptsiya superorganizma v biologii i meditsine. Eksperimental’naya i klinicheskaya gastroenterologiya 2014; № 107 (7): 72-85.
      39. Vakhitov T. Yu., Petrov L. N., Bondarenko V. M. Kontseptsiya probioticheskogo preparata, soderzhashchego original’nyye mikrobnyye metabolity ZHMEI 2005; № 5: 108-114.
      40. Neish A.S. Microbes in gastrointestinal health and disease.Gastroenterology 2009; 136: 65-80.
      41. Sonnenburg J.L, Fischbach M.A. Community Health care: therapeutic opportunities in the human microbiome. Sci Transl Med 2011 Apr 13; 3(78): 78ps12. doi: 10.1126/scitranslmed. 3001626.
      42. Caselli M, Vaira G, Calo G, Papini F, Holton J, Vaira D. Structural bacterial molecules as potential candidates for an evolution of the classical concept of probiotics. Adv Nutr 2011; 2: 372-376.
      43. Thompson J. A., Oliveira R. A., Djukovic A., Ubeda C., Xavier K. B. Manipulation of the Quorum-Sensing Signal AI-2 Affects the Antibiotic-Treated Gut Microbiota. Cell Reports 2015; 10.
      44. Verbeke F, De Craemer S, Debunne N, Janssens Y, Wynendaele E, Van de Wiele C, De Spiegeleer B. Peptides as Quorum Sensing Molecules: Measurement Techniques and Obtained Levels In vitro and In vivo. Front. Neurosci. 2017;11:183. doi: 10.3389/fnins.2017.00183.
      45. Kamada N, Nunez G. Regulation of the immune system by the resident intestinal bacteria. Gastroenterology 2014; 146(6): 1477-88.
      46. Karczewski J, Poniedzialek B, Adamski Z, Rzymski P. The effects of the microbiota on the host immune system. Autoimmunity 2014. DOI: 10.3109/08916934.2014.938322.
      47. Blander J. M., Longman R. S., Iliev I. D., Sonnenberg G. F., Artis D. Regulation of inflammation by microbiota interactions with the host. Nature Immunology 2017; 18(6): 851-860.
      48. Lebeer S., Bron P. A., Marco M.L., Van Pijkeren J-P., O’Conell Motherway M., Hill C., Pot B., Roos S., Klaenhammer T. Identification of probiotic effector molecules: present state and future perspectives. Current Opinion in Biotechnology 2018; 49: 217-223.
      49. Wallace D.C. The epigenome and the mitochondrion: bioenergetics and the environment. Gen Dev 2010; 24:1571-1573.
      50. Wallace B. D., Redinbo M.T. The Human Microbiome is a Source of Therapeutic Drug Targets. Curr Opin Chem Biol 2013; 17(3):379-384. Doi:10.1016/j.cbpa.2013.04.011.
      51. Gao D., Gao Z., Zhu G. Antioxidant effects of Lactobacillus plantarum via activation of transcription factor Nrf2. Food Funct 2013; 4:982-989.
      52. Mishra V, Shah C, Mokashe N, Chavan R, Yadav H, Prajapati J. Probiotics as potential antioxidants: A systematic review. J. Agric Food Chem. 2015; 63: 3615-3626.
      53. Prosekov A., Dyshlyuk L., Milentyeva I, Sukhish S, Babich O, Ivanova S, Pavskyi V., Shishin M., Matskova L. Antioxidant, antimicrobial and antitumor activity of bacteria of the genus bifidobacterium, selected from the gastrointestinal tract of human. Integr Mol Med 2015; 2(5): 295-303.
      54. Jones R.M., Neish A. S. Redox signaling mediated by the gut microbiota. Free Radical Biology and Medicine 2017; 105: 41-47 http://dx.doi.org/10.1016/j.freeradbiomed.2016.10.495.
      55. Wang Y., Wu Y., Wang Y., Xu H, Mei X, Yu D, Wang Y, Li W. Antioxidant Properties of Probiotic Bacteria. Nutrients 2017; 9:521; doi: 10.3390/nu9050521.
      56. Shenderov B. A. Mikroekologicheskaya epigenetika stressa, zabolevaniy, zdorov’ya i dolgoletiya. Vestnik vosstanovitel’noy meditsiny 2016; № 1: 21-8.
      57. El Aidy S, Stilling R. M. Dinan T. G., Cryan J. T. Microbiome to Brain: Unravelling the multidirectional axes of communication. Microbial Endocrinology: Interkingdom signaling in infectious disease and health. M. Lyte (ed). Advances in Experimental Medicine and Biology. Chapter 15. Springer International Publishing AG 2016: 301-336. Doi: 10.1007/978-3-319-20215_15.
      58. Shenderov B.A (2016) The microbiota as an epigenetic control mechanism. Chapter 11. In: Nibali L, Henderson B (eds) The human microbiota and chronic disease: dysbiosis as a cause of human pathology. 1st ed, J. Wiley & Sons, pp.179-197.
      59. Legent G, Norris V. Hybolites: novel therapeutic toolsfor targeting hyperstructure in bacteria. Recent Pat on Antiinfect Drug Discov 2009; 4 (2): 90-5.
      60. Norris V, Verrier C, Feuilloley M. Hybolites Revisited. Recent Pat on Antiinfect Drug Discov 2016; 11 (1): 1-13. Send Orders for Reprints to reprints@ benyhamscience.ae.
      61. Kashyap P. C., Chia N., Nelson H., Segal E., Elinav E. Microbiome at the Frontier of Personalized Medicine. Mayo Clin Proc 2017; 92(12): 1855-1864. https://doi.org/10.1016/j.mayocp.2017.10.004.
     


    Full text is published :
    METABIOTICS - NOVEL TECHNOLOGY OF PROTECTIVE AND TREATMENT OF DISEASES ASSOCIATED WITH MICROECOLOGICAL IMBALANCE IN HUMAN BEING. Experimental and Clinical Gastroenterology Journal. 2018;151(03):83-92
    Read & Download full text